Latest news for hhgregg (OTC:HGGG) Stock

hhgregg Inc is a part of the retail sector. It is a multi-regional retailer which provides an extensive selection of premium appliances, consumer electronics, home products and computers and tablets in its brick-and-mortar stores in the United States via hhgregg.com. The company's sales are categorized into four products; Appliances, which include refrigerators, cooking ranges, dishwashers; Consumer electronics such as 4K and OLED televisions and audio systems; Home Products which include furniture and mattresses and computer systems.

hhgregg Inc

Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 12.5 percent.

Earnings

News

Guidance

VIRX

Viracta Therapeutics Q3 2024 GAAP EPS $(0.27) Misses $(0.24) Estimate, Cash, Cash Equivalents, And Short-term Investments Of Approximately $21.1M Is Expected To Fund Operations Late Into The First Quarter Of 2025

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) with a Buy and maintains $47 price target.

Price Target

Reiteration

Analyst Ratings

Tempest Therapeutics, Inc. - Common Stock

TPST

HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target

CAVA: 18% &#x7C; <a href="https://www.benzinga.com//node/41935163">Cava Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net new restaurant openings outlook and same sales growth.</a>
&nbsp;
NTRA: 25% &#x7C; <a href="https://www.benzinga.com//node/41935174">Natera shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.</a>
&nbsp;
RIVN: 15% &#x7C; <a href="https://www.benzinga.com//node/41935201">Rivian Automotive shares are trading higher after the company announced a joint venture launch with Volkswagen for a total deal size worth up to $5.8 billion.</a>

Movers

Trading Ideas

CAVA

NTRA

RIVN

Market-Moving News for November 13th

Baird analyst Colin Sebastian maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and raises the price target from $44 to $51.

CART

Baird Maintains Outperform on Maplebear, Raises Price Target to $51

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $6 price target.

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

Management

PLUG

Plug Power Hosts 2024 Plug Symposium, Targets ~30% CAGR For Energy And Applications Businesses From 2025 To 2030; Appoints Sanjay Shrestha As New President

Sound Point Meridian Capital, Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPMC#NYSE">SPMC</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.57 by 50.88 percent. The company reported quarterly sales of $17.46 million which beat the analyst consensus estimate of $16.51 million by 5.74 percent.

Earnings Beats

SPMC

Sound Point Meridian Capital, Inc. Common Stock Q3 EPS $0.86 Beats $0.57 Estimate, Sales $17.46M Beat $16.51M Estimate

Baird analyst Colleen Kusy maintains Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) with a Outperform and raises the price target from $50 to $65.

SYRE

Baird Maintains Outperform on Spyre Therapeutics, Raises Price Target to $65

Baird analyst Catherine Ramsey maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $120 to $160.

Baird Maintains Outperform on Natera, Raises Price Target to $160

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $44 to $50.

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $50

WIIM

FLUT

Flutter Entertainment shares are trading higher after the company announced it has entered into non-discretionary arrangements with Goldman Sachs to repurchase ordinary shares.

As of Nov. 13, 2024, four stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Olo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>)</h3>
<ul>
<li>On Nov. 7, Olo posted better-than-expected quarterly earnings. &#8220;Team Olo executed well on our top priorities in the third quarter and positioned us to complete a successful 2024. We continued to win, retain, and expand with brands, we drove further innovation across our Order, Pay, and Engage product suites — including the general availability of Olo Pay&#8217;s card-present functionality on Qu point-of-sale systems — and we delivered revenue and bottom line performance that exceeded the high-end of our guidance ranges,&#8221; said Noah Glass, Olo&#8217;s Founder and CEO. The company's stock gained around 44% over the past month and <a href="https://www.benzinga.com/quote/OLO">has a 52-week high</a> of $7.04.</li>
<li>RSI Value: 90.08</li>
<li>OLO Price Action: Shares of Olo gained 10.6% to close at $6.90 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Couchbase Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>)</h3>
<ul>
<li>Couchbase will report financial results for its third quarter ended Oct. 31, on Tuesday, Dec. 3 after market close. The company's stock gained around 18% over the past month and has a <a href="https://www.benzinga.com/quote/BASE">52-week high</a> &lt;/em>&lt;/a> of $32.00.</li>
<li>RSI Value: 78.49</li>
<li>BASE Price Action: Shares of Couchbase gained 5.5% to close at $19.57 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</h3>
<ul>
<li>On Nov. 7, BILL Holdings reported better-than-expected first-quarter financial results and issued FY25 guidance above estimates. The company's stock jumped around 45% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 90.16</li>
<li>BILL Price Action: Shares of BILL gained 3.6% to close at $89.01 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)</h3>
<ul>
<li>Zscaler will release first quarter fiscal year 2025 earnings after the closing bell on Monday, Dec. 2. The company's stock jumped around 9% over the past five days and <a href="https://www.benzinga.com/quote/ZS">has a 52-week high</a> of $259.58.</li>
<li>RSI Value: 76.64</li>
<li>ZS Price Action: Shares of Zscaler climbed 4.8% to close at $209.04 on Tuesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/41896027/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

BASE

BILL

Top 4 Tech Stocks That May Keep You Up At Night This Quarter

KMDA

Kamada Raises FY24 Adjusted EBITDA Guidance To $32M-$35M, A 12% Increase Of The Midpoint From The Previous Guidance, And Reiterates Revenue Guidance Of $158M-$162M Vs. $160.47M Estimate

SWKS

Skyworks Solutions shares are trading lower after the company reported Q4 financial results and issued Q1 revenue guidance below estimates.

TD Cowen analyst Phil Nadeau downgrades Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) from Buy to Hold.

Downgrades

SYRS

TD Cowen Downgrades Syros Pharmaceuticals to Hold

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $112 to $116.

AXSM

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $116

PDCO

Patterson Dental Supply, A Subsidiary Of Patterson Companies, Announced An Agreement In Principle Between Patterson And PDS Health To Extend Their Strategic Relationship Through The End Of 2027

Mobilicom Enters Partnership With DT Research To Jointly Promote And Market Ground Control Station Products

Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) reported quarterly losses of $(2.29) per share which beat the analyst consensus estimate of $(2.85) by 19.65 percent.

Instil Bio Q2 2024 GAAP EPS $(2.29) Beats $(2.85) Estimate

Baird analyst Michael Ha maintains Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) with a Outperform and raises the price target from $67 to $86.

ASTH

Baird Maintains Outperform on Astrana Health, Raises Price Target to $86

hhgregg (HGGG) has released an update. On January 22, 2024, hhgregg, Inc. filed its Monthly Operating Reports for December 2023 with the U.S. Bankr...

Comments

hhgregg

News

Latest news for hhgregg (OTC:HGGG) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga